Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305
The family of poly (ADP-ribose) polymerases (PARPs) consists of 17 members, which have been demonstrated as having effects on a series of cellular processes, including DNA replication and repair. PARP inhibitors (PARPi) suppress DNA repair through “PARP trapping”, thus, constitute an important treat...
Main Authors: | Jingcao Zheng, Zhengyu Li, Wenjiao Min |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.979873/full |
Similar Items
-
Liquid chromatography-tandem mass spectrometry for pharmacokinetics evaluation of AZD5305, a selective PARP1 inhibitor, in mice
by: Gi Ju Lee, et al.
Published: (2023-08-01) -
The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas
by: Nazanin Majd, et al.
Published: (2020-11-01) -
The Antiviral Activities of Poly-ADP-Ribose Polymerases
by: Mathilde Malgras, et al.
Published: (2021-03-01) -
Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
by: Andrisha-Jade Inderjeeth, et al.
Published: (2022-11-01) -
Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review
by: Vivien Kin Yi Chan, et al.
Published: (2022-07-01)